Tvardi Therapeutics (TVRD) Preferred Stock Liabilities (2013 - 2025)
Tvardi Therapeutics (TVRD) posted Preferred Stock Liabilities of $85.5 million for Q1 2025, little changed sequentially from $85.5 million in Q4 2024, and little changed YoY from $85.5 million in Q1 2024.
Tvardi Therapeutics (TVRD) Preferred Stock Liabilities (2013 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Preferred Stock Liabilities for 4 years, with the latest figure at $85.5 million in Q1 2025.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $85.5 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $85.5 million (changed 0.0% YoY) and the FY2024 annual result came in at $85.5 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities held at $85.5 million in Q1 2025 per TVRD's latest filing, from $85.5 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $85.5 million in Q4 2023 and troughed at $85.5 million in Q4 2023.
- A 3-year average of $85.5 million and a median of $85.5 million in 2023 frame the typical range for Preferred Stock Liabilities.
- The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2024, down 0.0% in 2024.
- Over 3 years, Preferred Stock Liabilities stood at $85.5 million in 2023, then changed by 0.0% to $85.5 million in 2024, then changed by 0.0% to $85.5 million in 2025.
- According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $85.5 million, $85.5 million, and $85.5 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 85.50 Mn |
| Dec 31, 2024 | 85.50 Mn |
| Sep 30, 2024 | 85.50 Mn |
| Jun 30, 2024 | 85.50 Mn |
| Mar 31, 2024 | 85.50 Mn |
| Dec 31, 2023 | 85.50 Mn |
| Dec 31, 2013 | 65.59 Mn |
| Sep 30, 2013 | 65.59 Mn |
| Jun 30, 2013 | 949,000.00 |
| Mar 31, 2013 | 2.41 Mn |